• Explore /
  • Poster
  • / Phase 1 study of BPM 31510 (Ubidecarenone) in patients with advanced solid tumors (ST): Use of multiomics platform to evaluate reversal of Warburg effect.

Phase 1 study of BPM 31510 (Ubidecarenone) in patients with advanced solid tumors (ST): Use of multiomics platform to evaluate reversal of Warburg effect.

Abstract Poster

Authors

null

Ralph Zinner

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

Ralph Zinner , Peter Paul Yu , Niven R. Narain , Rangaprasad Sarangarajan , Michael Kiebish , Vivek Vishnudas , Yezhou Sun , Leonardo Rodrigues , Viacheslav R Akmaev , Susan Brouwer , Janice Stevens , Ely Benaim , Manish A. Shah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Cytotoxic and Other Novel Agents

Clinical Trial Registration Number

NCT01957735

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2539)

DOI

10.1200/jco.2015.33.15_suppl.2539

Abstract #

2539

Poster Bd #

255

Abstract Disclosures

Similar Posters

First Author: Manish A. Shah

First Author: Niven R. Narain

First Author: Iwona A. Lugowska

First Author: Ryan C. Lynch